
An innovative clinical trial at Gold Coast University Hospital (GCUH) is helping shape treatment for a common form of brain haemorrhage, using new technology designed to treat bleeding around the surface of the brain without the need to open the skull.
The first-in-human study led by GCUH's Interventional Neuroradiology team under Associate Professor Hal Rice, is evaluating a novel light-activated gel developed by Canadian medical technology company Northern Vascular Systems (NVS).
The investigational technology is being explored as a potential treatment for chronic subdural haematoma, a condition that occurs when blood slowly accumulates between the brain's surface and its protective outer covering.
Chronic subdural haematoma is one of the most common neurosurgical conditions affecting older adults and can develop after a fall or even a seemingly minor head injury.
As blood collects around the brain, it can place pressure on surrounding tissue, leading to symptoms such as headaches, confusion, memory difficulties, weakness and problems with balance or walking.
While surgery can be effective in draining the blood, the condition can return in some patients, sometimes requiring additional procedures and prolonged recovery.
Associate Professor Rice said the trial represents an exciting opportunity to evaluate a technology that could potentially improve treatment options for patients in the future.
"Chronic subdural haematoma can have a significant impact on a person's independence, quality of life and overall health," he said.
"This study allows us to explore a new approach that may provide greater precision when treating the blood vessels involved in the condition.”
The clinical trial combines an established minimally invasive procedure known as middle meningeal artery embolisation with a new light-activated gel.
During the procedure, specialists guide a tiny catheter through an artery in the wrist or groin to reach the small blood vessels supplying the membranes involved in the bleeding.
A specially developed liquid gel is then delivered directly into the targeted blood vessels. A small light at the tip of the catheter activates the gel, causing it to solidify and create a controlled blockage.
In simple terms, doctors use a tiny tube to deliver a special gel into the blood vessels contributing to the bleeding. Once exposed to light, the gel hardens, helping seal those vessels without opening the skull.
Associate Professor Rice said there is nothing else like it in the world.
“We’ve been doing this procedure for 10 years with different embolic agents, but what’s novel about this is that it doesn’t have any toxic solvents in it and stays in its liquid form until we turn on a light.”
“We can inject it, it can go exactly where we want it to go, and then when we’re happy, we can set it by turning on this ultraviolet light, which is built into the catheter.”
The goal is to reduce the blood flow contributing to the condition, allowing the body to gradually reabsorb the blood already collected around the brain.
The technology has been designed to give doctors greater control over where the gel is delivered and when it solidifies, potentially improving the precision of treatment.
Researchers will assess whether the device can be safely delivered and effectively block the targeted blood vessels. While the technology is still being investigated, it may eventually offer benefits such as reducing the risk of recurring bleeding, minimising the need for repeat procedures and supporting improved recovery.
The first six patients have now undergone treatment using the investigational NVS-1 System at GCUH, marking an important milestone in the early evaluation of the technology.
Participants continue to receive ongoing clinical assessments and follow-up brain imaging as part of the study.
“Patients certainly appreciate getting access to this new technology, which is life-changing for them.”
“Provided everything continues to work as well as it has been, we’ll continue to treat more patients and offer it to patients here on the Gold Coast.”
Participation in the trial reflects the Gold Coast Hospital and Health Service’s commitment to research, innovation and improving patient outcomes.
Clinical trials play a critical role in helping researchers evaluate promising new technologies before they become more widely available.
Findings from the study will contribute valuable knowledge to the development of future treatments for patients living with chronic subdural haematoma.